Tiapride, a substituted
benzamide derivative having chemical structure similar to
sulpiride and
metoclopramide, has been demonstrated to be a selective
dopamine receptor blocking agent of the central nervous system, especially the D2-receptor. The purpose of present study was to investigate efficacy and safety of
Tiapride in patients with various forms of
dyskinesia in long-term treatment. Severity of
dyskinesia was rated using the Abnormal
Involuntary Movement Scale (AIMS) developed by the National Institute of Mental Health (U.S.A.). Rating was made before, on week 1,2 and thereafter at 1 to 2 month interval. Adverse reaction was also checked on severity, onset, course and treatment. In patients with
parkinsonism, Hoehn Yahr's Grading was also administered. Based on these recording, overall improvement rating (OIR), overall safety rating (OSR) and usefulness, taken OIR and OSR in combination into account, were evaluated at the end of week 4 and at study completion. The results are summarized as follow;
Tiapride was given to 17 patients aged 39 to 81 (average: 62.8) in total, 9 with idiopathic
dyskinesia, 5 with Meige's syndrome and 3 with
parkinsonism developing
dyskinesia induced by
L-DOPA. Daily doses were ranged from 50 mg in patients with
parkinsonism to 600 mg in those with Meige's syndrome. Administration period was 35 to 748 days (average: 324 days). 1. Overall improvement rating (OIR); OIR showed that
Tiapride was "markedly improved" in 3 patients, "moderately improved" in 10 and "slightly improved" in 4 on week 4, increasing up to "markedly improved" in 8, "moderately improved" in 6 and "slightly improved" in 3, respectively at study completion.(ABSTRACT TRUNCATED AT 250 WORDS)